 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Product Name: | Peptide Tirzepatide | Usage: | Blood Sugar Control And Weight Loss |
|---|---|---|---|
| Specification: | 5mg, 10mg, 15mg And 30mg Per Vial | CAS NO.: | 2023788-19-2 |
| Grade: | Phamaceutical Grade | Delivery: | 100% |
| MOQ: | 1 Box (10 Vials) | FAD: | Approved |
Manufacturer Supply Peptide Tirzepatide Lyophilized Powder 5mg 10mg Vials CAS 2023788-19-2
Product desciption:
The FDA approved tirzepatide based on evidence from nine clinical trials of 7,769 participants with type 2 diabetes, of which 5,415 of these participants received tirzepatide. The trials were conducted at 673 sites in 24 countries, including Argentina, Australia, Brazil, Canada, India, Israel, Japan, Mexico, Russian Federation, South Korea, Taiwan, multiple European countries, and the United States (including Puerto Rico). All nine trials were used to assess safety and five of these trials were used to assess the efficacy of tirzepatide. The five trials used in the efficacy evaluation included 6,263 adult participants with type 2 diabetes. Four additional trials (NCT #03131687, NCT #03311724 NCT #03861052, NCT #03861039) were included in the safety evaluation, for a total of 7,769 adult participants with type 2 diabetes; therefore, the number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety. The benefits of tirzepatide for the treatment of adult participants with type 2 diabetes were primarily evaluated in five clinical trials. In two of these trials (NCT #03954834 and NCT #04039503), participants were randomly assigned to receive either tirzepatide or placebo injection weekly. Neither the patient nor the healthcare provider knew which treatment was being given until after the trials were completed. Treatment was given for 40 weeks. In the other three trials (NCT #3987919, 03882970, and 03730662), participants were randomly assigned to receive either tirzepatide or another antidiabetic medication, and the patient and provider knew which medication was being given. Treatment was given for 40 weeks to 104 weeks. In each trial, HbA1c was measured from the start of the trial to the end of the trial and compared between the tirzepatide group and the other groups.
Related products:
| GH 10iu 191AA | GH Fragment 176-191 | Adipotide |
| Melanotan II | Tirzepatide | Epithalon |
| Growth hormone | KPV | Oxytocin 2 |
| IGF1-LR3 | PT-141 | |
| HCG 5000iu Livzlon brand | P21 peptide | GHK-CU |
| HCG 5000iu | BPC-157 | Fox04 dri |
| TB-500 | CJC-1295 | DSIP |
| Hexarelin | HMG 75iu | AOD9604 |
| Ipamorelin | Sermorelin | MGF |
| Selank | Semaglutide | Peg-mgf |
| Semax | Tesamorelin | EPO 3000iu |
| Thymalin | Thymosin alpha | Follistatin 344 |
| GHRP2 | GHRP6 | Kisspeptin-10 Peptide |
| Gondorelin | IGF-1 DES | Dermorphin |
| IGF-LR3 | Melanotan | ACE-031 |
| Mots-C | Myostatin | AICAR |
| Please contact us for more products | ||
Product Photos:
Certifications:
Company:
FAQ:
Contact Person: jason
Tel: +86 17792557883
